Secondary causes of diabetes: a crossroad of endocrinology and oncology
Document Type
Review
Publication Date
5-1-2026
Abstract
Summary Cancer and diabetes share a bidirectional relationship, with cancer increasingly recognised as an associated factor of diabetes, both from the disease itself and its treatments. In this Review, we aim to: (1) summarise the distinct mechanisms of dysglycaemia arising from cancer and neuroendocrine tumour treatments, including targeted therapies such as PI3K–AKT–mTOR inhibitors, antibody–drug conjugates, immune checkpoint inhibitors, corticosteroids, and somatostatin receptor ligands; (2) examine the often overlooked aspect of the secondary cause of diabetes as an early manifestation of cancer; and (3) highlight research gaps and encourage a collaborative care approach to manage the rising rate of dysglycaemia as a result of cancer and its evolving treatments. To address the first two objectives, we incorporate relevant case vignettes to contextualise the discussions.
Keywords
Diabetes Mellitus, Endocrinology, Humans Medical Oncology, Neoplasms, Neuroendocrine Tumors
Publication Title
Lancet Diabetes and Endocrinology
ISSN
2213-8587
DOI
10.1016/S2213-8587(26)00027-6
Recommended Citation
Hee, Nicholas Ken Yoong; Lim, Quan Hziung; Khunti, Kamlesh; Ooi, Ying Guat; Yen, I. Weng; Saad, Marniza; Ekinci, Elif I.; Li, Hung Yuan; Vethakkan, Shireene R.; Chan, Juliana C.N.; and Lim, Lee Ling, "Secondary causes of diabetes: a crossroad of endocrinology and oncology" (2026). Research Publications (2026 to 2030). 121.
https://knova.um.edu.my/research_publications_2026_2030/121
Volume
14
Issue
5
First Page
422
Publisher
Elsevier